AP News

Overview of 3Q sales trends for Pfizer medicines


Here are worldwide third-quarter sales figures for some key Pfizer prescription drugs. Except for Enbrel and Prevnar, the decreases are due to generic competition.

PRODUCT NAME MAIN CONDITION/USE      3Q 2012 SALES   3Q 2011 SALES  PERCENT CHANGE

Lipitor High cholesterol        $749 million    $2.6 billion   down 71 percent 

Lyrica Fibromyalgia/pain       $1.04 billion   $961 million   up 8 percent

Enbrel (outside U.S.) Rheumatoid arthritis    $893 million    $957 million   down 7 percent

Prevnar 13 Pneumococcal vaccine    $868 million    $1.01 billion  down 14 percent

Celebrex Pain                    $676 million    $643 million   up 5 percent

Viagra Erectile dysfunction    $517 million    $493 million   up 5 percent

Norvasc High blood pressure     $319 million    $350 million   down 9 percent

Zyvox MRSA infections         $328 million    $321 million   up 2 percent

Sutent Multiple cancers        $294 million    $298 million   down 1 percent

Premarin/Prempro Menopause symptoms      $262 million    $267 million   down 2 percent

___

Source: Pfizer Inc.


Video Game Avenger
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus